To determine whether the Mcl-1 antagonism could render colon cancers sensitive to Bcl-xL neutralization and assess the influence of other pro-survival homologs on survival, we modified a panel of seven colon cancer lines to inducibly express either αMCL1 or αBFL1, and treated them with small molecules to selectively inhibit Bcl-2 (ABT-199), Bcl-xL (A-1331852), or Bcl-2 and Bcl-xL simultaneously (ABT-263). This evidence concerns the gene BCL2 and colonic neoplasm.